Ignace Vergote
MD, PhD
Professor and Head, Gynecologic Oncology
👥Biography 个人简介
Ignace Vergote is a Belgian gynecologic oncologist who led the landmark EORTC 55971 randomized trial comparing primary debulking surgery versus neoadjuvant chemotherapy followed by interval debulking for advanced ovarian, fallopian tube, and primary peritoneal carcinoma. His work established interval debulking as non-inferior to primary surgery in select patients. He has contributed to bevacizumab and PARP inhibitor maintenance trials in the combined ovarian/fallopian tube/peritoneal population and leads ENGOT (European Network for Gynaecological Oncological Trial) groups.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ignace Vergote 的研究动态
Follow Ignace Vergote's research updates
留下邮箱，当我们发布与 Ignace Vergote（University Hospitals Leuven）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment